2025-07-15　恭賀 張璧月醫檢師 當選『第16屆桃園市醫事檢驗師公會理事長』!!! 　 2025-06-30　恭賀 邱仁祥醫檢師 當選『第17屆南投縣醫檢師公會理事長』!!! 　 2023-07-01　會員如有權益相關問題及對本會有任何建議或意見回饋，歡迎利用電子信箱或致電本會，謝謝您!! 　 2015-02-02　醫事檢驗師宣誓誓詞，誓詞內容請至文件下載區查閱，並請協助推廣，謝謝！ 　

:::

歷 年 稿 件 內 容
 
*類別：
* 姓名： 黃柏蓉
投稿種類： 壁報
*中文投稿標題： 在肺腺癌病患的胸水積液中檢測表皮生長因子Exon 19及Exon 21突變之表現
*中文作者姓名列：
*中文服務單位：
*英文投稿標題：
*英文作者姓名列：
*英文服務單位：
* 投稿摘要： Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used in the treatment of non-small-cell lung cancer (NSCLC),and EGFR gene mutations are usually detected in NSCLC . A better response to EGFR TKIs and prolonged survival are related to EGFR mutations, including in frame deletions and point mutations. The EGFR mutation mainly exist in exons 18–21 and majority of EGFR mutations consist of deletions in exon 19 and exon 21 point mutation (L858R). Pleural effusion is a frequent complication of NSCLC .In this study, we detected exon 19 and exon 21 of EGFR mutations in pleural effusions and tried to evaluation their diagnostic utility in NSCLC. We obtained 50 samples including 36 malignant and14 non-malignant pleural effusions .Exons 19 and 21 of the EGFR gene were analyzed by Real-Time PCR (applied in LightCycler 480,ROCHE, Germany) and DNA Sequencing. EGFR mutations were detected in 13 of 36 specimens (36%).In-frame deletion mutations in exon 19 (4 of 13 specimens, 31%) and point mutations in exon 21 (9 of 13 specimens, 69%) were the most frequent mutations detected. All non-malignant samples demonstrated with H&E stain showed all negative result in Real-Time PCR. In contrast, pleural effusion cytology and CT guided biopsy were detected in patients with either NSCLC. Malignant pleural effusion cytology were detected in 20 of 36 specimens (55.6%) and CT guided biopsy were detected in 12 of 12 specimens (100%). Of several methods, CT guided biopsy was the most specific method for lung cancer and detecting EGFR mutations by Real-Time PCR from malignant pleural effusions was a feasible method to finding the subgroup with great response to TKIs therapy among patients in NLCLC.
*關鍵字1 ： EGFR mutations
*關鍵字2 ： tyrosine kinase inhibitor
*關鍵字3 ： adenocarcinoma
*關鍵字4 ： exon 19 deletions
*關鍵字5 ： exon 21 point mutation (L858R)
* 服務機關：
* 第一作者： 黃柏蓉
* 身分字號： *****19908
其他投稿作者：
身分字號：  
其他投稿作者：
身分字號：  
其他投稿作者：
身分字號：  
其他投稿作者：
身分字號：  
其他投稿作者：
身分字號：  
其他投稿作者：
身分字號：  
其他投稿作者：
身分字號：  
上傳稿件檔：
 開啟檔案
審查委員意見： 無意見
審查委員意見： OK
主任委員意見：
 
回上頁